COCP Cocrystal Pharma, Inc.
Price Chart
Executive Summary
Cocrystal Pharma appointed James Sapirstein as CEO, effective immediately, replacing co-CEOs Sam Lee and Jim Martin. Lee becomes President/CSO and Martin remains CFO. Sapirstein brings antiviral development and commercialization experience from Gilead, Tobira, and Contravir.
Actionable Insight
Monitor for any strategic pivot under the new CEO, particularly around pipeline acceleration or business development given Sapirstein's commercialization background. No immediate catalyst — the appointment is a management refresh for a clinical-stage biotech with a $14M market cap.
Key Facts
- James Sapirstein appointed CEO effective June 3, 2026, replacing co-CEOs Sam Lee and Jim Martin
- Sam Lee transitions to President and Chief Scientific Officer; Jim Martin remains CFO
- Sapirstein has participated in or led 23 product launches and held senior roles at Gilead Sciences, Tobira Therapeutics, and Contravir Pharmaceuticals
- Company plans to appoint Sapirstein to the Board of Directors
- No financial terms, guidance, or material financial data disclosed in the filing
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- CEO transition risk — new leadership may shift pipeline priorities or strategy
- Clinical-stage biotech with no approved products; execution risk remains high
- No financial guidance or pipeline timeline updates provided in this filing
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026965 |
| Exhibit: ex99-1.htm | 0001493152-26-026965 |
| Document: 0001493152-26-026965-index-headers.html | 0001493152-26-026965 |
| Document: 0001493152-26-026965-index.html | 0001493152-26-026965 |
| Document: 0001493152-26-026965.txt | 0001493152-26-026965 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
3d ago
|
8-K
| $1.02 awaiting T+1 | awaiting T+1 | — | $0.9900 (−2.46%) |
|
Jun 3, 2026
9d ago
|
8-K
| $1.06 $1.05 | ▼ −0.94% | ▼ −1.34% | $0.9900 (−6.60%) |
|
May 27, 2026
16d ago
|
DEFA14A
| $1.13 $1.12 | ▼ −0.89% | ▼ −1.12% | $0.9900 (−12.39%) |
|
May 26, 2026
17d ago
|
8-K
| $1.13 $1.12 | ▼ −0.89% | ▼ −0.90% | $0.9900 (−12.39%) |
|
May 15, 2026
28d ago
|
Press Release
| $1.20 $1.18 | ▼ −1.67% | ▼ −1.60% | $0.9900 (−17.50%) |
|
May 4, 2026
5w ago
|
EFFECT
| $1.31 $1.38 | ▼ −5.34% | ▼ −4.55% | $0.9900 (+24.43%) |
|
Apr 2, 2026
10w ago
|
8-K
| $1.51 $1.50 | ▼ −0.66% | ▼ −1.14% | $0.9900 (−34.44%) |
|
Mar 31, 2026
10w ago
|
8-K
| $1.01 $1.02 | ▲ +0.99% | ▲ +0.24% | $0.9900 (−1.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access